Qinglong High-Tech

Jiangxi Qinglong High-Tech Co., Ltd. is a Chinese pharmaceutical and biotechnology company specialized in the research, development, and production of innovative oncology treatments and high-purity botanical extracts. The company's leading drug candidate is Sinoporphyrin Sodium (also known as Cosiporfin Sodium or DVDMS), a novel second-generation photosensitizer currently in Phase 3 clinical trials for photodynamic therapy (PDT) in patients with esophageal cancer. Beyond its oncology pipeline, Qinglong High-Tech is a well-established manufacturer of pharmaceutical-grade plant extracts, including high-purity Ginkgo biloba extract, tea polyphenols, and silymarin, which are supplied to global markets. The company operates GMP-certified manufacturing facilities in Jiangxi Province and maintains strategic research collaborations with leading institutions such as the Peking University Cancer Hospital. Qinglong High-Tech integrates drug discovery, large-scale extraction, and finished dose manufacturing to address unmet needs in cancer and cardiovascular health.